summit tirzepatide hfpef trial Impact of Obesity Severity on the Effects of in HFpEF: The Obesity-related HFpEF: Tirzepatide benefits appear – Tirzepatide for HFPEF and Obesity

Focal neuropathies, including mononeuropathies and diabetic amyotrophy, present with acute onset pain and weakness in specific nerve distributions

A low-cost vial with subpotent or degraded semaglutide will not follow the dosage chart properly regardless of how precise your reconstitution and measurement techniques are

A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis

Standard titration protocol from clinical trials The Phase 2 NEJM trial used the following escalation schedule for the 12 mg dose group: Weeks 1 through 4: 2 mg once weekly (subcutaneous) Weeks 5 through 8: 4 mg once weekly Weeks 9 through 12: 8 mg once weekly Week 13 and beyond: 12 mg once weekly (maintenance dose) For the 8 mg target dose, the schedule was: Weeks 1 through 4: 2 mg once weekly Weeks 5 through 8: 4 mg once weekly Week 9 and beyond: 8 mg once weekly (maintenance dose) These titration schedules are not suggestions

PMID: 36949371

GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone produced in the gut after eating